Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring

Head and neck cancer (HNC), the seventh most common form of cancer worldwide, is a group of epithelial malignancies affecting sites in the upper aerodigestive tract. The 5-year overall survival for patients with HNC has stayed around 40-50% for decades, with mortality being attributable mainly to la...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2020-12, Vol.10 (1), p.48
Main Authors: Diez-Fraile, Araceli, Ceulaer, Joke De, Derpoorter, Charlotte, Spaas, Christophe, Backer, Tom De, Lamoral, Philippe, Abeloos, Johan, Lammens, Tim
Format: Article
Language:English
Subjects:
Biomarkers
Biopsy
Cancer therapies
Cardiovascular disease
circulating non-coding RNA
Decision making
Deoxyribonucleic acid
Diagnosis
DNA
DNA methylation
Gene expression
Head & neck cancer
head and neck cancer
Human papillomavirus
liquid biopsy
Medical prognosis
Metastasis
miRNA
Mortality
Non-coding RNA
Review
Risk assessment
RNA polymerase
Saliva
Transfer RNA
tRNA
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Head and neck cancer (HNC), the seventh most common form of cancer worldwide, is a group of epithelial malignancies affecting sites in the upper aerodigestive tract. The 5-year overall survival for patients with HNC has stayed around 40-50% for decades, with mortality being attributable mainly to late diagnosis and recurrence. Recently, non-coding RNAs, including tRNA halves, YRNA fragments, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been identified in the blood and saliva of patients diagnosed with HNC. These observations have recently fueled the study of their potential use in early detection, diagnosis, and risk assessment. The present review focuses on recent insights and the potential impact that circulating non-coding RNA evaluation may have on clinical decision-making in the management of HNC.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells10010048